Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 910,741
  • Shares Outstanding, K 42,919
  • Annual Sales, $ 4,230 K
  • Annual Income, $ -161,350 K
  • 60-Month Beta 0.66
  • Price/Sales 148.59
  • Price/Cash Flow N/A
  • Price/Book 22.03
Trade ACRS with:

Options Overview

Details
  • Implied Volatility 120.74%
  • Historical Volatility 70.61%
  • IV Percentile 6%
  • IV Rank 2.48%
  • IV High 1,380.93% on 03/17/20
  • IV Low 88.67% on 09/01/20
  • Put/Call Vol Ratio 1.09
  • Today's Volume 773
  • Volume Avg (30-Day) 1,109
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 4,501
  • Open Int (30-Day) 13,983

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.31
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +39.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.05 +38.81%
on 01/27/21
25.48 -12.56%
on 02/12/21
+4.80 (+27.46%)
since 01/26/21
3-Month
3.20 +596.25%
on 11/30/20
25.48 -12.56%
on 02/12/21
+18.97 (+573.11%)
since 11/25/20
52-Week
0.70 +3,082.86%
on 03/19/20
25.48 -12.56%
on 02/12/21
+21.05 (+1,711.38%)
since 02/26/20

Most Recent Stories

More News
Aclaris: 4Q Earnings Snapshot

WAYNE, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Thursday reported a loss of $13.2 million in its fourth quarter.

ACRS : 22.28 (+5.00%)
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

-- Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021

ACRS : 22.28 (+5.00%)
Aclaris Therapeutics to Participate in Upcoming Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker,...

ACRS : 22.28 (+5.00%)
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will...

ACRS : 22.28 (+5.00%)
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team

Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical...

AGN : 193.02 (+0.02%)
ASND : 154.97 (-2.33%)
KALV : 32.87 (-1.05%)
ACRS : 22.28 (+5.00%)
BHVN : 84.98 (+2.20%)
MNLO : 1.3500 (-2.17%)
SRRA : 14.74 (+1.83%)
BIOD : 0.65 (+6.56%)
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

ALXN : 152.75 (-0.59%)
LXRX : 7.19 (-3.88%)
ACRS : 22.28 (+5.00%)
BHVN : 84.98 (+2.20%)
GRTS : 13.57 (+2.26%)
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

UTHR : 167.18 (-0.96%)
BLRX : 3.09 (-4.33%)
INFI : 3.04 (-4.40%)
ACRS : 22.28 (+5.00%)
Aclaris Announces Pricing of Public Offering of Common Stock

Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten...

ACRS : 22.28 (+5.00%)
Aclaris Announces Proposed Public Offering of Common Stock

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer...

ACRS : 22.28 (+5.00%)
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive preliminary...

ACRS : 22.28 (+5.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

3rd Resistance Point 22.95
2nd Resistance Point 22.26
1st Resistance Point 21.74
Last Price 22.28
1st Support Level 20.53
2nd Support Level 19.84
3rd Support Level 19.32

See More

52-Week High 25.48
Last Price 22.28
Fibonacci 61.8% 16.01
Fibonacci 50% 13.09
Fibonacci 38.2% 10.17
52-Week Low 0.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar